Review of clinical tumor ablation advance in Asia

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Petrowsky H, Busuttil RW. Resection or ablation of small hepatocellular carcinoma: what is the better treatment? J Hepatol. 2008;49(4):502–504.
   PubMed Web of Science ®Google Scholar
• Sugiura N, Takara K, Ohto M, et al. Percutaneous intratumoral injection of ethanol under ultrasound imaging for treatment of small hepatocellular carcinoma. Acta Hepatologica Japonica. 1983;24:920.
   Google Scholar
• Zhou XD, Tang ZY, Yu YQ, et al. Clinical evaluation of cryosurgery in the treatment of primary liver cancer. Report of 60 cases. Cancer. 1988;61(9):1889–1892.
   PubMed Web of Science ®Google Scholar
• Seki T, Wakabayashi M, Nakagawa T, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer. 1994;74(3):817–825.
   PubMed Web of Science ®Google Scholar
• Kainuma O, Asano T, Aoyama H, et al. Combined therapy with radiofrequency thermal ablation and intra-arterial infusion chemotherapy for hepatic metastases from colorectal cancer. Hepatogastroenterology. 1999;46(26):1071–1077.
   PubMedGoogle Scholar
• Wu F, Chen WZ, Bai J, et al. Pathological changes in human malignant carcinoma treated with high-intensity focused ultrasound. Ultrasound Med Biol. 2001;27(8):1099–1106.
   PubMed Web of Science ®Google Scholar
• Huang K. The pilot experience of irreversible electroporation for medium-size liver cancers in the Asia. J Vasc Interv Radiol. 2013;24(759):e30.
   Google Scholar
• Liang P, Yu J, Lu MD, et al. Practice guidelines for ultrasound-guided percutaneous microwave ablation for hepatic malignancy. World J Gastroenterol. 2013;19(33):5430–5438.
   PubMed Web of Science ®Google Scholar
• Ye X, Fan W, Chen JH, et al. Chinese expert consensus workshop report: guidelines for thermal ablation of primary and metastatic lung tumors. Thorac Cancer. 2015;6(1):112–121.
   PubMed Web of Science ®Google Scholar
• Ye X, Fan W, Wang H, et al. Expert consensus workshop report: guidelines for thermal ablation of primary and metastatic lung tumors (2018 edition). J Cancer Res Ther. 2018;14(4):730–744.
   PubMed Web of Science ®Google Scholar
• Liu BD, Zhi XY. Expert consensus on image-guided radiofrequency ablation of pulmonary tumors–2015 edition. Chin Clin Oncol. 2015;4:27.
   PubMed Web of Science ®Google Scholar
• Na DG, Lee JH, Jung SL, et al. Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: consensus statement and recommendations. Korean J Radiol. 2012;13(2):117–125.
   PubMed Web of Science ®Google Scholar
• Kim JH, Baek JH, Lim HK, et al. 2017 Thyroid radiofrequency ablation guideline: Korean society of thyroid radiology. Korean J Radiol. 2018;19(4):632–655.
   PubMed Web of Science ®Google Scholar
• Hahn SY, Shin JH, Na DG, et al. Ethanol ablation of the thyroid nodules: 2018 consensus statement by the Korean society of thyroid radiology. Korean J Radiol. 2019;20(4):609–620.
   PubMed Web of Science ®Google Scholar
• Rhim H. Review of Asian experience of thermal ablation techniques and clinical practice. Int J Hyperthermia. 2004;20(7):699–712.
   PubMed Web of Science ®Google Scholar
• Petrick JL, Florio AA, Znaor A, et al. International trends in hepatocellular carcinoma incidence, 1978–2012. Int J Cancer. 2020;147(2):317–330.
   PubMed Web of Science ®Google Scholar
• Shiina S, Yasuda H, Muto H, et al. Percutaneous ethanol injection in the treatment of liver neoplasms. AJR Am J Roentgenol. 1987;149(5):949–952.
   PubMed Web of Science ®Google Scholar
• Teratani T, Ishikawa T, Shiratori Y, et al. Hepatocellular carcinoma in elderly patients: beneficial therapeutic efficacy using percutaneous ethanol injection therapy. Cancer. 2002;95(4):816–823.
   PubMed Web of Science ®Google Scholar
• Huang GT, Lee PH, Tsang YM, et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma - a prospective study. Ann Surg. 2005;242(1):36–42.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Brace CL, Lee FT, et al. Principles of and advances in percutaneous ablation. Radiology. 2011;258(2):351–369.
   PubMed Web of Science ®Google Scholar
• Yang B, You X, Yuan ML, et al. Transarterial ethanol ablation combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus. Hepat Mon. 2016;16(8):e37584.
   PubMed Web of Science ®Google Scholar
• Zhou P, Liu X, Li R, et al. Percutaneous coagulation therapy of hepatocellular carcinoma by combining microwave coagulation therapy and ethanol injection. Eur J Radiol. 2009;71(2):338–342.
   PubMed Web of Science ®Google Scholar
• Liang P, Yu J, Yu XL, et al. Percutaneous cooled-tip microwave ablation under ultrasound guidance for primary liver cancer: a multicentre analysis of 1363 treatment-naive lesions in 1007 patients in China. Gut. 2012;61(7):1100–1101.
   PubMed Web of Science ®Google Scholar
• Lu MD, Xu HX, Xie XY, et al. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. J Gastroenterol. 2005;40(11):1054–1060.
   PubMed Web of Science ®Google Scholar
• Dong B, Liang P, Yu X, et al. Percutaneous sonographically guided microwave coagulation therapy for hepatocellular carcinoma: results in 234 patients. AJR Am J Roentgenol. 2003;180(6):1547–1555.
   PubMed Web of Science ®Google Scholar
• Ding J, Jing X, Liu J, et al. Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma. Eur J Radiol. 2013;82(9):1379–1384.
   PubMed Web of Science ®Google Scholar
• Xu J, Zhao Y. Comparison of percutaneous microwave ablation and laparoscopic resection in the prognosis of liver cancer. Int J Clin Exp Pathol. 2015;8:11665–11669.
   PubMed Web of Science ®Google Scholar
• Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107(4):569–577; quiz 578.
   PubMed Web of Science ®Google Scholar
• Kim YS, Lim HK, Rhim H, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013;58(1):89–97.
   PubMed Web of Science ®Google Scholar
• Lee MW, Kang D, Lim HK, et al. Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival. Eur Radiol. 2020;30(4):2391–2400.
   PubMed Web of Science ®Google Scholar
• Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321–328.
   PubMed Web of Science ®Google Scholar
• Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252(6):903–912.
   PubMed Web of Science ®Google Scholar
• Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012;57(4):794–802.
   PubMed Web of Science ®Google Scholar
• Fang Y, Chen W, Liang X, et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(1):193–200.
   PubMed Web of Science ®Google Scholar
• Ng KKC, Chok KSH, Chan ACY, et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg. 2017;104(13):1775–1784.
   PubMed Web of Science ®Google Scholar
• Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129(1):122–130.
   PubMed Web of Science ®Google Scholar
• Lin SM, Lin CJ, Lin CC, et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005;54(8):1151–1156.
   PubMed Web of Science ®Google Scholar
• Lin SM, Lin CJ, Lin CC, et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < = 4cm. Gastroenterology. 2004;127:1714–1723.
   PubMed Web of Science ®Google Scholar
• Yu J, Liang P, Yu XL, et al. Needle track seeding after percutaneous microwave ablation of malignant liver tumors under ultrasound guidance: analysis of 14-year experience with 1462 patients at a single center. Eur J Radiol. 2012;81(10):2495–2499.
   PubMed Web of Science ®Google Scholar
• Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am. 1995;1(1):73–81.
   PubMedGoogle Scholar
• Shiina S. Image-guided percutaneous ablation therapies for hepatocellular carcinoma. J Gastroenterol. 2009;44(Suppl.19):122–131.
   PubMed Web of Science ®Google Scholar
• Shiina S, Teratani T, Obi S, et al. Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology. 2002;62(Suppl.1):64–68.
   PubMed Web of Science ®Google Scholar
• Koda M, Murawaki Y, Hirooka Y, et al. Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: an analysis of 16 346 treated nodules in 13 283 patients. Hepatol Res. 2012;42(11):1058–1064.
   PubMed Web of Science ®Google Scholar
• Thomson KR, Cheung W, Ellis SJ, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol. 2011;22(5):611–621.
   PubMed Web of Science ®Google Scholar
• Dupuy DE, Zagoria RJ, Akerley W, et al. Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol. 2000;174(1):57–59.
   PubMed Web of Science ®Google Scholar
• Nishida T, Inoue K, Kawata Y, et al. Percutaneous radiofrequency ablation of lung neoplasms: a minimally invasive strategy for inoperable patients. J Am Coll Surg. 2002;195(3):426–430.
   PubMed Web of Science ®Google Scholar
• Yamakado K, Hase S, Matsuoka T, et al. Radiofrequency ablation for the treatment of unresectable lung metastases in patients with colorectal cancer: a multicenter study in Japan. J Vasc Interv Radiol. 2007;18(3):393–398.
   PubMed Web of Science ®Google Scholar
• Lu Q, Cao W, Huang L, et al. CT-guided percutaneous microwave ablation of pulmonary malignancies: results in 69 cases. World J Surg Oncol. 2012;10:80–80.
   PubMed Web of Science ®Google Scholar
• Gobara H, Arai Y, Kobayashi T, et al. Percutaneous radiofrequency ablation for patients with malignant lung tumors: a phase II prospective multicenter study (JIVROSG-0702). Jpn J Radiol. 2016;34(8):556–563.
   PubMed Web of Science ®Google Scholar
• Li X, Wang J, Li W, et al. Percutaneous CT-guided radiofrequency ablation for unresectable hepatocellular carcinoma pulmonary metastases. Int J Hyperthermia. 2012;28(8):721–728.
   PubMed Web of Science ®Google Scholar
• He W, Hu XD, Wu DF, et al. Ultrasonography-guided percutaneous microwave ablation of peripheral lung cancer. Clin Imaging. 2006;30(4):234–241.
   PubMed Web of Science ®Google Scholar
• Wang W, Liu W, Zhou J, et al. High intensity focused ultrasound treatment for symptomatic uterine fibroids: preliminary results. Zhonghua Chao Sheng Ying Xiang Xue Za Zhi. 2002;11:161–163.
   Google Scholar
• Ren XL, Zhou XD, Zhang J, et al. Extracorporeal ablation of uterine fibroids with high-intensity focused ultrasound: imaging and histopathologic evaluation. J Ultrasound Med. 2007;26(2):201–212.
   PubMed Web of Science ®Google Scholar
• Ren XL, Zhou XD, Yan RL, et al. Sonographically guided extracorporeal ablation of uterine fibroids with high-intensity focused ultrasound: midterm results. J Ultrasound Med. 2009;28(1):100–103.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang J, Han ZY, et al. Effectiveness of ultrasound-guided percutaneous microwave ablation for symptomatic uterine fibroids: a multicentre study in China. Int J Hyperthermia. 2016;32(8):876–880.
   PubMed Web of Science ®Google Scholar
• Kim YS, Rhim H, Tae K, et al. Radiofrequency ablation of benign cold thyroid nodules: initial clinical experience. Thyroid. 2006;16(4):361–367.
   PubMed Web of Science ®Google Scholar
• Feng B, Liang P, Cheng Z, et al. Ultrasound-guided percutaneous microwave ablation of benign thyroid nodules: experimental and clinical studies. Eur J Endocrinol. 2012;166(6):1031–1037.
   PubMed Web of Science ®Google Scholar
• Yue W, Wang S, Yu S, et al. Ultrasound-guided percutaneous microwave ablation of solitary T1N0M0 papillary thyroid microcarcinoma: initial experience. Int J Hyperthermia. 2014;30(2):150–157.
   PubMed Web of Science ®Google Scholar
• Teng D, Sui G, Liu C, et al. Long-term efficacy of ultrasound-guided low power microwave ablation for the treatment of primary papillary thyroid microcarcinoma: a 3-year follow-up study. J Cancer Res Clin Oncol. 2018;144(4):771–779.
   PubMed Web of Science ®Google Scholar
• Turtulici G, Orlandi D, Corazza A, et al. Percutaneous radiofrequency ablation of benign thyroid nodules assisted by a virtual needle tracking system. Ultrasound Med Biol. 2014;40(7):1447–1452.
   PubMed Web of Science ®Google Scholar
• Hong MJ, Baek JH, Choi YJ, et al. Radiofrequency ablation is a thyroid function-preserving treatment for patients with bilateral benign thyroid nodules. J Vasc Interv Radiol. 2015;26(1):55–61.
   PubMed Web of Science ®Google Scholar
• Sung JY, Baek JH, Kim YS, et al. One-Step ethanol ablation of viscous cystic thyroid nodules. AJR Am J Roentgenol. 2008;191(6):1730–1733.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Baek JH, Ha EJ, et al. Cystic versus predominantly cystic thyroid nodules: efficacy of ethanol ablation and analysis of related factors. Eur Radiol. 2012;22(7):1573–1578.
   PubMed Web of Science ®Google Scholar
• Sung JY, Baek JH, Kim KS, et al. Single-session treatment of benign cystic thyroid nodules with ethanol versus radiofrequency ablation: a prospective randomized study. Radiology. 2013;269(1):293–300.
   PubMed Web of Science ®Google Scholar
• Baek JH, Ha EJ, Choi YJ, et al. Radiofrequency versus ethanol ablation for treating predominantly cystic thyroid nodules: a randomized clinical trial. Korean J Radiol. 2015;16(6):1332–1340.
   PubMed Web of Science ®Google Scholar
• Wu F, Wang ZB, Zhu H, et al. Feasibility of US-guided high-intensity focused ultrasound treatment in patients with advanced pancreatic cancer: initial experience. Radiology. 2005;236(3):1034–1040.
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang X, Liu H, et al. Percutaneous microwave ablation versus laparoscopic partial nephrectomy for cT1a renal cell carcinoma: a propensity-matched cohort study of 1955 patients. Radiology. 2020;294(3):698–706.
   PubMed Web of Science ®Google Scholar
• Lee DH, Kim JW, Lee JM, et al. Laparoscopic liver resection versus percutaneous radiofrequency ablation for small single nodular hepatocellular carcinoma: comparison of treatment outcomes. Liver Cancer. 2021;10(1):25–37.
   PubMed Web of Science ®Google Scholar
• Lee DH, Lee JM, Kim PN, et al. Whole tumor ablation of locally recurred hepatocellular carcinoma including retained iodized oil after transarterial chemoembolization improves progression-free survival. Eur Radiol. 2019;29(9):5052–5062.
   PubMed Web of Science ®Google Scholar
• Lee DH, Lee JM, Yu MH, et al. Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MR can help determine the treatment method for HCC. Eur Radiol. 2019;29(6):3122–3131.
   PubMed Web of Science ®Google Scholar
• Ha EJ, Baek JH, Che Y, et al. Radiofrequency ablation of benign thyroid nodules: recommendations from the Asian conference on tumor ablation task force. Ultrasonography. 2021;40(1):75–82.
   PubMed Web of Science ®Google Scholar
• Ju JX, Zeng QJ, Xu EJ, et al. Intraprocedural contrast-enhanced ultrasound-CT/MR fusion imaging assessment in HCC thermal ablation to reduce local tumor progression: compared with routine contrast-enhanced ultrasound. Int J Hyperthermia. 2019;36(1):785–793.
   PubMed Web of Science ®Google Scholar
• Li K, Su Z, Xu E, et al. Evaluation of the ablation margin of hepatocellular carcinoma using CEUS-CT/MR image fusion in a phantom model and in patients. BMC Cancer. 2017;17(1):61–61.
   PubMed Web of Science ®Google Scholar
• Numata K, Fukuda H, Morimoto M, et al. Use of fusion imaging combining contrast-enhanced ultrasonography with a perflubutane-based contrast agent and contrast-enhanced computed tomography for the evaluation of percutaneous radiofrequency ablation of hypervascular hepatocellular carcinoma. Eur J Radiol. 2012;81(10):2746–2753.
   PubMed Web of Science ®Google Scholar
• Lee JY, Choi BI, Chung YE, et al. Clinical value of CT/MR-US fusion imaging for radiofrequency ablation of hepatic nodules. Eur J Radiol. 2012;81(9):2281–2289.
   PubMed Web of Science ®Google Scholar
• Song KD, Lee MW, Rhim H, et al. Percutaneous US/MRI fusion-guided radiofrequency ablation for recurrent subcentimeter hepatocellular carcinoma: technical feasibility and therapeutic outcomes. Radiology. 2018;288(3):878–886.
   PubMed Web of Science ®Google Scholar
• Minami Y, Minami T, Takita M, et al. Radiofrequency ablation for hepatocellular carcinoma: clinical value of ultrasound-ultrasound overlay fusion for optimal ablation and local controllability. Hepatol Res. 2020;50(1):67–74.
   PubMed Web of Science ®Google Scholar
• Liu FY, Yu XL, Liang P, et al. Microwave ablation assisted by a real-time virtual navigation system for hepatocellular carcinoma undetectable by conventional ultrasonography. Eur J Radiol. 2012;81(7):1455–1459.
   PubMed Web of Science ®Google Scholar
• Peng Z, Chen S, Wei M, et al. Advanced recurrent hepatocellular carcinoma: treatment with sorafenib alone or in combination with transarterial chemoembolization and radiofrequency ablation. Radiology. 2018;287(2):705–714.
   PubMed Web of Science ®Google Scholar
• Zhu K, Huang J, Lai L, et al. Medium or large hepatocellular carcinoma: sorafenib combined with transarterial chemoembolization and radiofrequency ablation. Radiology. 2018;288(1):300–307.
   PubMed Web of Science ®Google Scholar
• Yuan H, Lan Y, Li X, et al. Large hepatocellular carcinoma with local remnants after transarterial chemoembolization: treatment by sorafenib combined with radiofrequency ablation or sorafenib alone. Am J Cancer Res. 2019;9:791–799.
   PubMed Web of Science ®Google Scholar
• Feng X, Xu R, Du X, et al. Combination therapy with sorafenib and radiofrequency ablation for BCLC stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study. Am J Gastroenterol. 2014;109(12):1891–1899.
   PubMed Web of Science ®Google Scholar
• Weng DS, Zhou J, Zhou QM, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J. Immunother. 2008;31(1):63–71.
   PubMed Web of Science ®Google Scholar
• Ma H, Zhang Y, Wang Q, et al. Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation. Cancer Biol Ther. 2010;9(11):903–907.
   PubMed Web of Science ®Google Scholar
• Liang S, Niu L, Xu K, et al. Tumor cryoablation in combination with natural killer cells therapy and herceptin in patients with HER2-overexpressing recurrent breast cancer. Mol Immunol. 2017;92:45–53.
   PubMed Web of Science ®Google Scholar
• Lin M, Liang S, Wang X, et al. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment. J Cancer Res Clin Oncol. 2017;143(12):2607–2618.
   PubMed Web of Science ®Google Scholar
• Lin M, Liang S, Wang X, et al. Short-term clinical efficacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell for treating metastatic pancreatic cancer. Immunol Lett. 2017;186:20–27.
   PubMed Web of Science ®Google Scholar
• Lin M, Liang SZ, Wang XH, et al. Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer. Immunol Res. 2017;65(4):880–887.
   PubMed Web of Science ®Google Scholar
• Lin M, Xu K, Liang S, et al. Prospective study of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced renal cell cancer. Immunol Lett. 2017;184:98–104.
   PubMed Web of Science ®Google Scholar
• Yang Y, Qin Z, Du D, et al. Safety and short-term efficacy of irreversible electroporation and allogenic natural killer cell immunotherapy combination in the treatment of patients with unresectable primary liver cancer. Cardiovasc Intervent Radiol. 2019;42(1):48–59.
   PubMed Web of Science ®Google Scholar
• Zhou P, Liang P, Dong B, et al. Phase I clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma. Cancer Biol Ther. 2011;11(5):450–456.
   PubMed Web of Science ®Google Scholar
• Yu MA, Liang P, Yu XL, et al. Multiple courses of immunotherapy with different immune cell types for patients with hepatocellular carcinoma after microwave ablation. Exp Ther Med. 2015;10(4):1460–1466.
   PubMed Web of Science ®Google Scholar